Nchi: Israeli
Lugha: Kiingereza
Chanzo: Ministry of Health
PITOLISANT AS HYDROCHLORIDE
TRUEMED LTD, ISRAEL
N07XX11
FILM COATED TABLETS
PITOLISANT AS HYDROCHLORIDE 4.45 MG
PER OS
Required
BIOPROJET PHARMA, FRANCE
PITOLISANT
Wakix is indicated• In adults for the treatment of narcolepsy with or without cataplexy. • To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP).
2020-03-15
ءاودلا لوانت نع تفقوت اذإ ءاقلت نم سكيكاو لوانت نع ئجافم لكشب فقوتت لا .هلوانتب بيبطلا كدشري املاطل ءاودلا لوانت ةلصاوم كيلع .ةيحصلا كتلاح ىلع نسحت أرط ولو ىتح ،بيبطلا ةراشتسإ نودب ءاودلاب جلاعلا نع فقوتلا زوجي لا .كسفن ةرم لك يف يئاودلا رادقملا نم دكأتلاو ءاودلا عباط صيخشت بجي !ةمتعلا يف ةيودأ لوانت زوجي لا .كلذ رملأا مزل اذإ ةيبطلا تاراظنلا عض .ءاود اهيف لوانتت .يلديصلا وأ بيبطلا رشتسإ ،ءاودلا اذه لامعتسإ لوح ةيفاضإ ةلئسأ كيدل ترفوت اذإ ةيبناجلا ضارعلأا )4 ضارعلأا ةمئاق نم شهدنت لا .نيلمعتسملا ضعب ىدل ةيبناج ً اضارعأ ببسي دق سكيكاو لامعتسإ نإ ،ءاود لكب امك .اهنم ً ايأ يناعت لاأ زئاجلا نم .ةيبناجلا :)نيجلاعتم 10 نيب نم دحاو نم رثكأ ىدل رهظت دق( ً ادج ةعئاش ةيبناج ضارعأ مونلا ءانثأ يدادسنلإا سفنلا عاطقنإ ةدمجلا ضرم نودب وأ عم يبايتنلإا مونلا عادص - :)نيجلاعتم 10 نيب نم دحاو ىتح ىدل رهظت دق( ةعئاش ةيبناج ضارعأ مونلا ءانثأ يدادسنلإا سفنلا عاطقنإ ةدمجلا ضرم نودب وأ عم يبايتنلإا مونلا قلق ،مونلا يف لكاشم ،مونلا يف تابوعص - )وغيتريڤ( "راود" ـب روعشلا - مدلا طغض عافترإ - لاهسإ ،نطبلا يف جاعزنإب روعشلا ،نايثغ - ةحارلا مدعو ملأ - لكاشم ،بائتكإ ،ةيبصع ،قلق ،مونلا يف تابوعص - مونلا يف تابارطضإ ،)وغيتريڤ( "راود" ـب روعشلا ،عادص - فاجترإ ،نز Soma hati kamili
1 1. NAME OF THE MEDICINAL PRODUCT Wakix 4.5 mg Wakix 18 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Wakix 4.5 mg film-coated tablet Each tablet contains pitolisant hydrochloride equivalent to 4.45 mg of pitolisant. Wakix 18 mg film-coated tablet Each tablet contains pitolisant hydrochloride equivalent to 17.8 mg of pitolisant. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Wakix 4.5 mg film-coated tablet White, round, biconvex film-coated tablet, 3.7 mm diameter, marked with “5” on one side. Wakix 18 mg film-coated tablet White, round, biconvex film-coated tablet, 7.5 mm diameter marked with “20” on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Wakix is indicated In adults for the treatment of narcolepsy with or without cataplexy. To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION NARCOLEPSY WITH OR WITHOUT CATAPLEXY Treatment should be initiated by a physician experienced in the treatment of sleep disorders. Posology Wakix should be used at the lowest effective dose, depending on individual patient response and tolerance, according to an up-titration scheme, without exceeding the dose of 36 mg/day: - Week 1: initial dose of 9 mg (two 4.5 mg tablets) per day. - Week 2: the dose may be increased to 18 mg (one 18 mg tablet) per day or decreased to 4.5 mg (one 4.5 mg tablet) per day. - Week 3: the dose may be increased to 36 mg (two 18 mg tablets) per day. At any time the dose can be decreased (down to 4.5 mg per day) or increased (up to 36 mg per day) according to the physician assessment and the patient’s response. The total daily dose should be administered as a single dose in the morning during breakfast. 2 _Maintenance of efficacy_ As long-term efficacy data are limited Soma hati kamili